JP2016535071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535071A5 JP2016535071A5 JP2016543477A JP2016543477A JP2016535071A5 JP 2016535071 A5 JP2016535071 A5 JP 2016535071A5 JP 2016543477 A JP2016543477 A JP 2016543477A JP 2016543477 A JP2016543477 A JP 2016543477A JP 2016535071 A5 JP2016535071 A5 JP 2016535071A5
- Authority
- JP
- Japan
- Prior art keywords
- fxa variant
- variant protein
- composition
- acid sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 | |
| US61/881,834 | 2013-09-24 | ||
| PCT/IB2014/064564 WO2015044836A1 (en) | 2013-09-24 | 2014-09-16 | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535071A JP2016535071A (ja) | 2016-11-10 |
| JP2016535071A5 true JP2016535071A5 (enExample) | 2017-10-12 |
| JP6429885B2 JP6429885B2 (ja) | 2018-11-28 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543477A Expired - Fee Related JP6429885B2 (ja) | 2013-09-24 | 2014-09-16 | 組換えヒト凝固第ｘａ因子タンパク質の不均一集団を含む組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9757434B2 (enExample) |
| EP (1) | EP3049434A1 (enExample) |
| JP (1) | JP6429885B2 (enExample) |
| KR (1) | KR101988705B1 (enExample) |
| CN (2) | CN105579468A (enExample) |
| AR (1) | AR097732A1 (enExample) |
| AU (1) | AU2014326257B2 (enExample) |
| BR (1) | BR112016005899A8 (enExample) |
| CA (1) | CA2924981C (enExample) |
| HK (1) | HK1218760A1 (enExample) |
| IL (2) | IL244258A0 (enExample) |
| MX (1) | MX373466B (enExample) |
| MY (1) | MY173548A (enExample) |
| PE (1) | PE20160877A1 (enExample) |
| RU (1) | RU2648144C2 (enExample) |
| SA (1) | SA516370751B1 (enExample) |
| SG (1) | SG11201601221XA (enExample) |
| TW (1) | TWI631134B (enExample) |
| WO (1) | WO2015044836A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2950813B1 (en) | 2013-01-31 | 2019-09-04 | Pfizer Inc | Compositions and methods for counteracting factor xa inhibition |
| JP6429885B2 (ja) | 2013-09-24 | 2018-11-28 | ファイザー・インク | 組換えヒト凝固第ｘａ因子タンパク質の不均一集団を含む組成物 |
| PT3472314T (pt) | 2016-06-17 | 2021-06-18 | Alexion Pharma Inc | Preparação de derivados do fator xa |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| MX2007001294A (es) | 2004-08-17 | 2008-03-04 | Zlb Behring Gmbh | Polipeptidos modificados que dependen de vitamina k. |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX2008006313A (es) | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| BRPI0816837B1 (pt) * | 2007-09-28 | 2022-10-18 | Portola Pharmaceuticals, Inc | Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica |
| EP2300497B1 (en) | 2008-06-24 | 2012-08-08 | Octapharma AG | A process of purifying coagulation factor viii |
| US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| PT2453910T (pt) | 2009-07-15 | 2016-12-07 | Portola Pharm Inc | Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento |
| ES2739503T3 (es) * | 2010-07-09 | 2020-01-31 | Bioverativ Therapeutics Inc | Moléculas de cadena simple procesables y polipéptidos producidos usándolas |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| EP2760887B1 (en) | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| US9145552B2 (en) | 2012-07-25 | 2015-09-29 | Catalyst Biosciences, Inc. | Modified factor X polypeptides and uses thereof |
| EP2950813B1 (en) | 2013-01-31 | 2019-09-04 | Pfizer Inc | Compositions and methods for counteracting factor xa inhibition |
| JP6429885B2 (ja) | 2013-09-24 | 2018-11-28 | ファイザー・インク | 組換えヒト凝固第ｘａ因子タンパク質の不均一集団を含む組成物 |
| JP6629744B2 (ja) | 2013-11-01 | 2020-01-15 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 第Ｘａ因子の半減期を延ばす組成物および方法 |
| KR20160093731A (ko) | 2014-01-24 | 2016-08-08 | 화이자 인코포레이티드 | 뇌내 출혈을 치료하기 위한 조성물 및 방법 |
-
2014
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molino et al. | Different types of aqueous two‐phase systems for biomolecule and bioparticle extraction and purification | |
| DK2537862T3 (en) | A method of purifying coagulation factor VIII | |
| EP3040346B1 (en) | Process for the purification of granulocyte colony stimulating factor, g-csf | |
| RU2596408C2 (ru) | Способ очистки человеческого фактора, стимулирующего колонии гранулоцитов, из рекомбинантных е. coli | |
| FI4011908T3 (fi) | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| PL409838A1 (pl) | Rekombinowane wirusy stowarzyszone z adenowirusem (AAV), kompozycje , wyizolowane białko kapsydu, wyizolowana lub syntetyczna cząsteczka kwasu nukleinowego, sposób wytwarzania rekombinowanych wirusów, komórki gospodarza, białka obejmujące fragment białka kapsydu AAV, sztuczne białka, rekombinowane wirusy, cząsteczki, sposoby dostarczania transgenu do komórki , sposób identyfikacji serotypu sekwencji wirusa (AAV), zestaw diagnostyczny, sposób izolacji nowych wirusów, nowe serotypy wirusa, wyizolowane wirusy, rekombinowana komórka, zastosowanie wirusa | |
| JP2016535071A5 (enExample) | ||
| CN101616930B (zh) | 疏水性蛋白质的纯化方法 | |
| WO2017019432A1 (en) | Methods for purifying adenovirus vectors | |
| JP2017505620A5 (enExample) | ||
| JP2014507368A5 (enExample) | ||
| US8536302B2 (en) | Dockerin polypeptide and method of purifying recombinant fused protein using the same | |
| Zhang et al. | A p H‐induced, intein‐mediated expression and purification of recombinant human epidermal growth factor in Escherichia coli | |
| JP2015515969A5 (enExample) | ||
| CN104136121A (zh) | 减少离子交换色谱中的pH漂移 | |
| JP6232130B2 (ja) | ダルベポエチンアルファの精製方法 | |
| RU2016108608A (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ГЕТЕРОГЕННЫЕ ПОПУЛЯЦИИ РЕКОМБИНАНТНЫХ БЕЛКОВ ЧЕЛОВЕЧЕСКОГО ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Ха | |
| CN102675445A (zh) | 一种类泛素修饰蛋白及其制备和应用 | |
| Lee et al. | Purification of human antibodies from transgenic corn using aqueous two‐phase systems | |
| CN105541994B (zh) | 一种血小板生成素或其变体或衍生物的纯化方法 | |
| CN102443055B (zh) | 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺 | |
| Schirmer et al. | Reduction of product‐related species during the fermentation and purification of a recombinant IL‐1 receptor antagonist at the laboratory and pilot scale | |
| CN110831956A (zh) | 重组蛋白 | |
| Misterova et al. | Optimization of a Purification Method for the Recombinant Platelet-Derived Growth Factor rhPDGF-BB Expressed in the Methylotrophic Yeast Pichia Pastoris |